Platelets and diabetes: A complex association

Platelets

Volumn 26, Issue 3, 2015, Pages 267-268

  Jagroop, Anita ^a   Mikhailidis, Dimitri P ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Drugs; Glycaemia; Hyperactivity; Platelet

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; PROSTACYCLIN;

ANTICOAGULATION; DISEASE ASSOCIATION; EDITORIAL; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SMOKING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; DIABETES MELLITUS, TYPE 2; METABOLISM;

BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 84925945820     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.746456     Document Type: Editorial

References (23)

1. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010;7:251-259.
2. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983;32:217-221.
3. Mikhailidis DP, Mikhailidis AM, Barradas MA, Dandona P. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism 1983;32:717-721.
4. Barradas MA, Mikhailidis DP, Dandona P. The effect of nonesterified fatty acids on vascular ADP-degrading enzyme activity. Diab Res Clin Pract 1987;3:9-19.
5. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010;8:828-837.
6. Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers. Platelets 2012;23:565-570.
7. Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327-337.
8. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002;45:1034-1037.
9. Anfossi G, Russo I, Doronzo G, Trovati M. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets 2007;7:228-249.
10. Papanas N, Maltezos E. Oral antidiabetic agents: Anti-atherosclerotic properties beyond glucose lowering?. Curr Pharm Des 2009;15:3179-3192.
11. Dolasik I, Sener SY, Celebi K, Aydin ZM, Korkmaz U, Canturk Z, The effect of metformin on mean platelet volume in diabetic patients. Platelets 2012 Apr 12. [Epub ahead of print].
12. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011;405:79-84.
13. Ferreiro JL, Angiolillo DJ, Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Diseases. Curr Pharm Des 2012;18:5273-5293.
14. Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010;16:3808-3814.
15. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003;9:2445-2464.
16. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003;54:507-530.
17. Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S. Platelet indices in diabetes mellitus: Indicators of diabetic microvascular complications. Hematology 2011;16:86-89.
18. Zhong ZL, Han M, Chen S. Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus. Int J Ophthalmol 2011;4:182-185.
19. Nübol M, Ayhan M, Güney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. Platelets 2012;23:475-480.
20. Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res 2009;41:585-593.
21. Harmsze AM, van Werkum JW, Moral F, Ten Berg JN, Hackeng CM, Klungel OH, de Boer A, Deneer VH. Sulfonylureas and onclopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98-102.
22. Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS, Hong SP, Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2012 Aug 7. [Epub ahead of print].
23. Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, O'Reilly M, Foley DP, Thompson CJ, Agha A, Smith D, et al. Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets 2012;23:439-446.